Pursue diligence · N4 · Chronic infection
Opportunity Score: 66/100 · Evidence: Moderate
Worth a closer look — not a mandate to form a company This card inherits the parent leftover’s score. It is not a second ranking.
Inhaled antibiotics remain SoC; novel CF infection programs are thin after review.
Not medical advice, not a recommendation to buy or sell any security, and not a claim that any opportunity should be funded.
A score or thesis. Always shown with evidence and a way to kill it.
Approved inhaled antibiotics remain SoC; novel CF infection programs are thin after review.
A published number with a source and a date. You can check it.
PA is 23.3% of cultured patients (52.0% in 2009). NTM is 11.6% of mycobacterial cultures and 18.7% among ages 60+. Inhaled tobramycin remains 51.2% of PA-positive ages ≥6; inhaled aztreonam 30.3%. Fewer cultures since 2020 affect ascertainment.
A filter or count this project computed, such as the reviewed CF map.
After review, industry investigational crowding on N4 is low: BiomX BX004. Academic phage and IV gallium are visible. AP-PA02 had no matching active CF-like trial in this snapshot. N4 scores 66/100 with evidence Moderate.
What we think the fact and analysis mean. Not a score yet.
SoC occupies chronic suppression. The remaining question is persistent PA or NTM on that SoC, not an untreated infection market. Falling PA is real and partly measurement-sensitive.
Why this leftover might be a real product question.
Approved inhaled antibiotics are still widely used and novel CF infection programs are thin. A manufacturable, regulated modality against persistent PA or NTM would sit in a reviewed industry column that currently has one crowding unit.
Why it might already be solved, or never be a new company.
If BX004 works, it becomes the incumbent rather than leaving a hole. If PA keeps falling on HEMT, the addressable chronic-infection group shrinks. Phage CMC, resistance, and regulation are messy. NTM in older adults may be aging and ascertainment more than a CF-specific phage story.
Reasons a skeptical reader would push back.
Assumptions the bet needs. If these fail, the thesis fails.
Chronic PA or NTM still drives residual lung disease on HEMT; phage or another modality can be manufactured and regulated; culture-ascertainment decline is not the whole PA story.
A pre-committed rule. If this happens, drop the thesis rather than talking yourself into it.
Kill if BX004 or similar phage succeeds as a broad incumbent or if PA/NTM prevalence and inhaled-antibiotic use keep collapsing without a new product.
Pursue diligence on a defined persistent-infection segment. Do not pitch 'CF infection' as empty.
This card inherits the parent need score. It is not a second ranking and not a funding recommendation.